RAS mutations in thyroid cancer
- PMID: 23873720
- PMCID: PMC3755930
- DOI: 10.1634/theoncologist.2013-0072
RAS mutations in thyroid cancer
Abstract
In recent years, our understanding of the genetic alterations underlying thyroid oncogenesis has greatly expanded. The use of molecular markers, including RAS, in the management of thyroid carcinoma is also increasing. This review summarizes the current literature surrounding RAS and discusses its potential as a diagnostic and prognostic indicator in the management of thyroid cancer.
Keywords: Molecular markers; RAS; Thyroid cancer; Thyroid nodules.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
References
-
- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167. - PubMed
-
- DeLellis RA, Lloyd RV, Heitz PU, et al., editors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours.
-
- Nikiforova MN, Nikiforov YE. Molecular Testing of Thyroid FNA Samples. In: Nikiforov YE, Biddinger PW, Thompson LDR, editors. Diagnostic Pathology and Molecular Genetics of the Thyroid. Baltimore, MD: Lippincott Williams & Wilkins; 2009. pp. 94–102.
-
- Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7:569–580. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
